Clinical and economic review of erlotinib in non-small-cell lung cancer.
about
Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell linesEpidermal growth factor receptor: an important target in esophageal cancer.Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis.Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells.
P2860
Clinical and economic review of erlotinib in non-small-cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical and economic review of erlotinib in non-small-cell lung cancer.
@en
type
label
Clinical and economic review of erlotinib in non-small-cell lung cancer.
@en
prefLabel
Clinical and economic review of erlotinib in non-small-cell lung cancer.
@en
P2860
P356
P1476
Clinical and economic review of erlotinib in non-small-cell lung cancer.
@en
P2093
Josh J Carlson
P2860
P304
P356
10.1586/ERP.12.42
P577
2012-08-01T00:00:00Z